Compounds and uses thereof for the modulation of hemoglobin
US-2016031865-A1 · Feb 4, 2016 · US
Compounds and uses thereof for the modulation of hemoglobin
US9981939B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9981939-B2 |
| Application number | US-201414776603-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 10, 2014 |
| Priority date | Mar 15, 2013 |
| Publication date | May 29, 2018 |
| Grant date | May 29, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.
First claim
Opening claim text (preview).
What is claimed is: 1. A compound selected from: or a pharmaceutically acceptable salt thereof. 2. The compound of claim 1 , wherein the compound is: or a pharmaceutically acceptable salt thereof. 3. The compound of claim 1 , wherein the compound is: or a pharmaceutically acceptable salt thereof. 4. The compound of claim 1 , wherein the compound is: or a pharmaceutically acceptable salt thereof. 5. The compound of claim 1 , wherein the compound is: or a pharmaceutically acceptable salt thereof. 6. The compound of claim 1 , wherein the compound is: or a pharmaceutically acceptable salt thereof. 7. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
Assignees
Inventors
Classifications
Antineoplastic agents · CPC title
for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Drugs for disorders of the blood or the extracellular fluid · CPC title
Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9981939B2 cover?
- Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.
- Who is the assignee on this patent?
- Global Blood Therapeutics Inc
- What technology area does this patent fall under?
- Primary CPC classification C07D401/04. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue May 29 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).